Heparin-bonded expanded polytetrafluoroethylene vascular graft for femoropopliteal and femorocrural bypass grafting: 1-year results

Bosiers et al. 20061

Dendermonde, Bonheiden, and Genk, Belgium

Primary patency of GORE® PROPATEN® Vascular Graft

N=55
1 year 84%

 

 

Patient characteristics*

Characteristic N %
Rutherford classification*  
3 58 58%
4 16 16%
5 26 26%
Runoff vessels*  
0 7 7
1 51 51%
2 21 21%
3 21 21%
Hypertension** 62 72%
Diabetes** 24 28%
Renal insufficiency** 8 9%

Study details

  • All grafts were thin-wall, ringed, 6 mm diameter configurations
  • Angiography performed immediately after graft implantation to detect technical failures
  • Postoperatively, patients received clopidogrel (75 mg / day) for the first month after surgery, low-molecular-weight heparin (0.6 mL / day) for the first three weeks, and aspirin (100 mg / day) we indefinitely
  • 96% secondary patency at one-year for above-knee fem-pop bypass

In the light of these in vivo results, we speculate that a decrease in platelet and thrombus deposition on the CBAS ePTFE graft surface may have contributed to the promising 1-year patency rates in our clinical series. Although amelioration of intimal hyperplasia is not the primary target of heparinization technology, it is intriguing to consider the possibility that the CBAS graft surface might simultaneously address two sources of graft failure: thrombosis and intimal hyperplasia. — M. Bosiers

Our findings… indicate that use of this graft is an excellent option for infrainguinal bypass grafting in patients with peripheral vascular disease when autologous vein is not available. — M. Bosiers

*N = 100 limbs

**N = 86 patients

1. Bosiers M, Deloose K, Verbist J, et al. Heparin-bonded expanded polytetrafluoroethylene vascular graft for femoropopliteal and femorocrural bypass grafting: 1-year results. Journal of Vascular Surgery 2006;43(2):313-319.

Residents of some states have the right to opt-out of the “sharing” or “selling” of their personal information. Gore does not "sell" the personal information of website users. Gore may "share" the personal information of website users, as standard advertising practice meant to offer you a more personalized service.

If you want to opt-out from Gore “sharing” your personal information, click on Opt-Out of Sharing to turn off the targeting cookies that we share with our advertising partners in order to provide you with personalized information. Disabling sharing will stop the use of cookies to targeted advertising but you may still see generic Gore ads.

Please note that your exercising of the rights outlined will have no adverse effect on the price and quality of our goods or services.

Opt-Out of Sharing

You Have Successfully Opted Out of the Sharing of Your Personal Information

Please note that if you clear your cookies and then use another device or browser, etc. your opt-out status is not transferred to the new device or browser.